These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Parkinson disease: an update. Gazewood JD; Richards DR; Clebak K Am Fam Physician; 2013 Feb; 87(4):267-73. PubMed ID: 23418798 [TBL] [Abstract][Full Text] [Related]
5. Parkinson's Disease. Reich SG; Savitt JM Med Clin North Am; 2019 Mar; 103(2):337-350. PubMed ID: 30704685 [TBL] [Abstract][Full Text] [Related]
6. An update on the diagnosis and treatment of Parkinson disease. Rizek P; Kumar N; Jog MS CMAJ; 2016 Nov; 188(16):1157-1165. PubMed ID: 27221269 [No Abstract] [Full Text] [Related]
7. Parkinson's disease: making the diagnosis, selecting drug therapies. Scharre DW; Mahler ME Geriatrics; 1994 Oct; 49(10):14-6, 20-3. PubMed ID: 7926845 [TBL] [Abstract][Full Text] [Related]
8. New and emerging treatments for Parkinson disease. Fung VS Med J Aust; 2015 Apr; 202(6):283-4. PubMed ID: 25832138 [No Abstract] [Full Text] [Related]
9. Drugs for Parkinson's disease. Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688 [TBL] [Abstract][Full Text] [Related]
10. Approach to the patient with Parkinson disease. Johnson KE Prim Care; 2015 Jun; 42(2):205-15. PubMed ID: 25979582 [TBL] [Abstract][Full Text] [Related]
11. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio). Stocchi F; Marconi S Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107 [TBL] [Abstract][Full Text] [Related]
12. Motor fluctuations in Parkinson's disease. Weiner WJ Rev Neurol Dis; 2006; 3(3):101-8. PubMed ID: 17047575 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological treatment of Parkinson disease: a review. Connolly BS; Lang AE JAMA; 2014 Apr 23-30; 311(16):1670-83. PubMed ID: 24756517 [TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease: therapeutic choices and timing decisions in patient management. Interview by Wayne Kuznar. Stacy M Geriatrics; 1999 Oct; 54(10):44-9; quiz 50. PubMed ID: 10542860 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications. Müller T Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910 [TBL] [Abstract][Full Text] [Related]
16. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies. Pahwa R J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613 [TBL] [Abstract][Full Text] [Related]
17. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States. Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691 [TBL] [Abstract][Full Text] [Related]
18. When the going gets tough: how to select patients with Parkinson's disease for advanced therapies. Worth PF Pract Neurol; 2013 Jun; 13(3):140-52. PubMed ID: 23487815 [TBL] [Abstract][Full Text] [Related]
19. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. Oertel W; Schulz JB J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098 [TBL] [Abstract][Full Text] [Related]
20. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease. Regidor I; Benita V; Del Álamo de Pedro M; Ley L; Martinez Castrillo JC Clin Neuropharmacol; 2017; 40(3):103-107. PubMed ID: 28452905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]